Rheumatoid Arthritis Clinical Trial
— PARISOfficial title:
Efficacy and Safety of Rituximab in Pakistani Patients With Rheumatoid Arthritis (RA)
Verified date | April 2016 |
Source | Pakistan Institute of Medical Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A study to determine the efficacy and safety of rituximab in Pakistani patients with rheumatoid arthritis (RA) who have been inadequately controlled with standard disease modifying anti rheumatic drugs (DMARDs).
Status | Completed |
Enrollment | 74 |
Est. completion date | December 2012 |
Est. primary completion date | July 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Able and willing to give written informed consent. 2. Men and women aged 18-80 years, inclusive. 3. Patients with RA for at least 6 months. 4. DAS28 score > 3.70 at baseline. 5. Inadequate response to methotrexate (MTX), for at least 4 weeks using a stable dose of 15mg/week. Glucocorticoids (<10 mg/day prednisone or equivalent) permitted if stable for at least 4 weeks prior to baseline. 6. Use of Non-steroidal anti-inflammatory drugs (NSAIDs) permitted if stable dose for at least 2 weeks prior to baseline. 7. Patients of reproductive potential (males and females) must be willing to use a reliable method of contraception (e.g. contraceptive pill, intrauterine device (IUD) or a physical barrier) during the study and for 12 months after last Rituximab administration. 8. If female and of childbearing potential, a negative serum pregnancy test within 2 weeks prior to baseline. Exclusion Criteria: Exclusion Criteria Related to RA 1. Bed bound or wheelchair bound patients. 2. Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA Exclusions Related to Medications 1. History of severe allergic or anaphylactic reactions to a biologic agent or known hypersensitivity to any component of Rituximab or to murine proteins. 2. Previous treatment with any approved or investigational biologic agent for RA. 3. Concurrent treatment with any biologic agent for any indication. 4. Receipt of any vaccine within 4 weeks prior to baseline (it was recommended that a patient's vaccination record and the need for immunization prior to receiving Rituximab should be carefully investigated). 5. Intolerance to or contraindications to drugs required for the treatment of adverse event of Rituximab (e.g., paracetamol, anti-histamines, hydrocortisone, anti-emetics or histamine-receptor 1 (H1) blockers). 6. Intra-articular or parenteral glucocorticoids within 4 weeks prior to baseline. Exclusions for General Safety/Health 1. Any surgical procedure, including bone / joint surgery / synovectomy (including joint fusion or replacement) within 12 weeks prior to baseline or planned within 24 weeks of randomization. 2. Evidence of any severe or significant medical condition(s) or disease(s) that, in the view of the investigator, prohibited participation in the study. 3. Evidence of significant uncontrolled concomitant disease such as, but not limited to, nervous system, renal, hepatic, endocrine or gastrointestinal disorders which, in the investigator's opinion, would have precluded patient participation. 4. Significant cardiac (heart failure of New York Heart Association (NYHA) class IV) or pulmonary disease (including obstructive pulmonary disease). 5. Known active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic infections), or a known active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with intravenous (IV) anti-infectives within 4 weeks prior to baseline or completion of oral anti-infectives within 2 weeks prior to baseline. 6. History of serious recurrent or chronic infection. (for screening for a chest infection a chest radiograph will be performed at screening if not performed within 12 weeks prior to screening). 7. Primary or secondary immunodeficiency (history of, or currently active), including known history of human immunodeficiency (HIV) infection. 8. Pregnancy or breast feeding. 9. Known history of active cancer during the past 5 years, including solid tumours, hematological malignancies and carcinoma in situ (except basal cell and squamous cell carcinoma of the skin that have been excised and cured). 10. Currently active alcohol or drug abuse or history of alcohol or drug abuse within 24 weeks prior to baseline. Exclusion criteria related to laboratory findings: 1. Positive serum human chorionic gonadotropin measured within two weeks prior to the first infusion of study drug 2. Positive test for hepatitis B surface antigen (HBsAg) or for hepatitis C serology 3. Positive hepatitis B core antibody (HBcAb) associated with positive hepatitis B virus (HBV) detection (> 29 IU/L or > 169 copies/mL) 4. Hemoglobin < 8.0 g/dL 5. Absolute neutrophil count < 1.5 × 103/µL 6. Concentration of serum immunoglobulin G (IgG) and/or immunoglobulin M (IgM) below 5.0 and 0.40 mg/mL, respectively. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Prof. Abid Z. Farooqi | Aga Khan University, Fatima Memorial Hospital, Fauji Foundation Hospital, Rawalpindi |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improvement in Disease Activity Assessment Score (DAS-28) | To determine the percentage of previously inadequately-controlled RA patients achieving improvement in their disease activity level post treatment with Rituximab at 6 months interval using Disease Activity Score in 28 selected joints (DAS-28). | 6 months | |
Secondary | Status of disease activity level using DAS 28 score | To determine the percentage of such RA patients achieving improvement in their disease activity level post treatment at 12 months interval using DAS-28. | 12 months | |
Secondary | Status of disease response to treatment using the ACR 20/50/70 response criteria | Using the ACR 20/50/70 response criteria | 12 months | |
Secondary | Status of disease response to treatment using the EULAR response criteria | using the EULAR response criteria | 12 months | |
Secondary | Documenting serious adverse events during the trial period | Any event leading to hospitalization or death during the trial period | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |